A Phase 2 Exploratory, Multicenter, Open-Label Trial to Determine the Safety and Preliminary Clinical Activity of GEN1046 in Combination With Anticancer Agents in Subjects With Advanced Endometrial Cancer
Latest Information Update: 06 May 2024
At a glance
- Drugs Acasunlimab (Primary) ; Pembrolizumab (Primary)
- Indications Carcinoma; Endometrial cancer
- Focus Therapeutic Use
- Sponsors Genmab
Most Recent Events
- 29 Apr 2024 Planned primary completion date changed from 1 Jun 2028 to 1 Apr 2028.
- 29 Apr 2024 Planned initiation date changed from 30 Apr 2024 to 1 Oct 2023.
- 29 Apr 2024 Status changed from not yet recruiting to withdrawn prior to enrolment. (Enrollment challenged by availability of other treatment options)